ÿWPCY• •• •   ûÿ• 2 Í   • •   B   • Z   R   • !   ¬   •   Í   #|
x   •   UNIVERSAL Laserjet Series II   UNIVHPII.PRS ô•x ••••
Œ•   ••@É §ÍÇ•; ,•ð ••t•07•Mx @Courier 10cpi Courier 10cpi Bold ûÿ• 2
    • X• ÿ   • •   W•   ð•ÿÿ‰ ? x x x ,••   5wô•
x þ•6•X•   ••@É “8Á•; X•@þþþþþþþÿÿÿÿÿ•ÿÿþÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿþÿÿl•ÿÿ‰ ? x
 x x ,•• • ûàô•x Ð••• •   ••`É w•Á•; X••ÿÿÿþþþþÿÿÿÿÿÿÿÿÿþÿÿÿÿÿÿÿÿÿÿÿÿÿ
ÿÿÿÿþÿÿÿÿÿÿÿW   T•   #| x   •þÄ:ÄuË‹N•èÀ•   -‹ð“+•
•ÿÿÿÿë•‹N•è••   «•ÿWÿÿÿÿ •• •   ûÿ• 2 •• ÿÿ•   B   • V   P   ÿÿZ
  ¦   ÿÿ•   • Courier 10cpi ð•ÿÿ‰ ?   ,Ð•• °•°•<•••• •ÐÐ•Ð   X•°•••
`   ¸•••h•À•••p•È• •x•Ð (#•%Ø'0*^,à.81•3è5@8˜:ð<H? Aÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿ
ÿÿÿÿÿÿÿÿÿ   X•°•”•ì•D•œ•ô•L•¤•ÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿ
ÿÿÿ   °•ÿÿÐ •ÐŠÐ••
 <•••<•t•• •ÐÐ•• °•°•X•X•• •ÐÑ•# ô•x þ•6•X•   ••@É “8Á•; 5wX•@# •ÑÁ`
|•d&> ÁIN RESPONSE, PLEASEƒ•Á`ô•d&? ÁREFER TO: M890119ƒ••••Ð•• <•t•<•
„•• •ÐÐ•Ð   X•°•”•ì•D•œ•ô•L•¤•ÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿ
ÿÿ   X•d•”•ì•
D•œ•ô•L•¤•ü•ÿÿÿ
                    ÿÿÿÿÐ •ÐÁàL•H•% ÁFebruary 14, 1989ƒ••Á ”•”•• ÁÁ ì•
ì•• ÁÁ D•D•• ÁÁ œ•œ•! ÁÁ ô•ô•& ÁÁ L•L•+ ÁÁ ¤•¤•0 ÁÁ ü•ü•5 ÁÁ ü•ü•5 Á
 Ã•ÃR E V I S E DÄ•Ä•••••Ô•• •‰ ? `   • •ÔMEMORANDUM FOR:Á œ•œ•! ÁVi
ctor Stello, Jr.•Á ”•”•• ÁÁ ì•ì•• ÁÁ D•D•• ÁÁ œ•œ•! ÁExecutive Directo
r for Operations••Á ”•”•• ÁÁ ì•ì•• ÁÁ D•D•• ÁÁ œ•œ•! ÁHarold R. Denton
, Director•Á ”•”•• ÁÁ ì•ì•• ÁÁ D•D•• ÁÁ œ•œ•! ÁOffice of Governmental
and Public Affairs••Ô•• •‰ ? ••• •ÔFROM:Á ì•ì•• ÁÁ D•D•• ÁÁ œ•œ•! ÁSa
muel J. Chilk, Secretary /S/••Ô•• •‰ ? •• •ÔSUBJECT:Â °•ì•ì•• ÂÂ X•
D•D•• ÂÂ X•œ•œ•! ÂSTAFF REQUIREMENTS © BRIEFING ON MEDICAL•USE OF BY©P
RODUCT MATERIALS, 10:00 A.M.,•THURS¬DAY, JANUARY 19, 1989, COMMISSIONE
RS'•CON¬FERENCE ROOM, ONE WHITE FLINT NORTH,•ROCKVILLE, MARYLAND (OPEN
 TO PUBLIC•ATTENDANCE)ÆT$œ•Æ••••The Commission* was briefed by the sta
ff on current and future•activities for monitor
ing and improving public health and safety•in the medical uses of nucl
ear by©product materials.••The Commission requested the staff to:••Ô••
  •‰ ? X•• •Ô©©Â X•”•”•• ÂReview the need for increasing the inspectio
n frequency of•community hospitals.ÆT$”•Æ••Ô•• •‰ ? °•• •Ô©©Â X•”•”••
 ÂDetermine if Agreement States meet NRC's minimum frequency•of inspec
tion guidelines and review the programs of states•which exceed staff's
 goal of a minimum of one inspection•every three years (including thei
r rationale and need for•Ô•• •‰ ? Ð • •Ôgreater frequency of inspecti
on).Ã•ÃÄ•ÄÃ•ÃÄ•ÄÁ ü•ü•5 ÁÁ ü•ü•5 ÁÁ ü•ü•5 ÁÁ ü•ü•5 ÁÁ ü•ü•5 ÁÁ ü•ü•5 Á
ÆT$”•Æ•Ô•• •‰ ? ˜!• •ÔÁ ”•”•• ÁÁ ì•ì•• Á(Ã•ÃGPAÄ•Ä)Á œ•œ•! ÁÁ ô•ô•& Á
Á L•L•+ Á(SECY Suspense: 3/3/89)••Ô•• •‰ ? (#• •Ô©©Â X•”•”•• ÂRetain
 the rigor of reporting requirements for misadminis-trations in any pr
oposed redefinition of this term. The•rationale for any such redefini
tion should be provided in•the staff paper accompanying the proposed r
ule on quality•assurance and reporting requi
rements of misadministrations,•unless staff believes the issue must be
 resolved on a•higher priority basis.ÆT$”•Æ•Ô•• •‰ ? (• •ÔÁ ”•”•• ÁÁ
 ì•ì•• Á(EDO)Á œ•œ•! ÁÁ ô•ô•& ÁÁ L•L•+ Á(SECY Suspense: 4/28/89)••••_
______________•* Commissioners Rogers and Curtiss were not present.•Ô
• •P-•   à.à.à.X•X•• Ô•Ð•• X•X•„•X•• •ÐÁà••H•+ Á© 2 ©ƒ•••Ô••
•‰ ? X•• •Ô©©Â X•”•”•• ÂSubmit an information paper which outlines sta

ff's•activities in the following areas (as previously requested•by Com
missioner Rogers):ÆT$”•Æ••Ô•• •‰ ? x•• •ÔÁ ”•”•• Á(1)Â °•ì•ì•• ÂEffor
ts in monitoring medical community performance•and the development of
indicators of trends in•performance.ÆT$ì•Æ••Ô•• •‰ ? ˜•• •ÔÂ X•”•”••
Â(2)Â X•ì•ì•• ÂDiscussions with the medical community on establishing•
a visiting fellows program with NMSS, including the•associated costs o
f such a program. ÆT$ì•Æ•Á ”•”•• ÁÁ ì•ì•• Á(EDO) (SECY
Suspense: 4/14/89)••Ô•• •‰ ? ••• •Ô©©Â X•”•”•• ÂProvide a status bri
efing on NRC activities for improving•oversi
ght of medical use licensees.ÆT$”•Æ•Ô•• •‰ ? ••• •ÔÁ ”•”•• ÁÁ ì•ì•• Á
(EDO)Á œ•œ•! ÁÁ ô•ô•& ÁÁ L•L•+ Á(SECY Suspense: 7/89)••Ô•• •‰ ? ••
•Ô©©Â X•”•”•• ÂInteract with the Advisory Committee on the Medical Use
s of•Isotopes in developing the performance evaluation factors•which t
he staff proposes to submit to the Commission in•September 1989.ÆT$”•Æ
•Ô•• •‰ ? À•• •ÔÁ ”•”•• ÁÁ ì•ì•• Á(EDO)Á œ•œ•! ÁÁ ô•ô•& ÁÁ L•L•+ Á(SE
CY Suspense: 9/89)••Ô•• •‰ ? P•• •Ô©©Â X•”•”•• ÂReview the U.S. Food
 and Drug Administration's (FDA's)•quality assurance requirement and r
egulatory experiences•for possible application by the NRC.ÆT$”•Æ••Ô••
 •‰ ? p•• •Ô©©Â X•”•”•• ÂEnsure highly qualified NRC inspectors and pr
ofessional•inspection programs.ÆT$”•Æ••Ô•• •‰ ? È•• •Ô©©Â X•”•”•• ÂPr
opose, in the Commission's Five Year Plan, the necessary•resource adju
stments believed appropriate to respond to the•concerns outlined in th
e Commission briefing (e.g., compu-ter¬ized treatment planning, availa
bility of trained•technologists, monoclonal
antibodies, etc.).ÆT$”•Æ••Ô•• •‰ ? x•• •Ô©©Â X•”•”•• ÂWork closely wi
th the Agreement States to ensure that any•proposed requirements affec
ting NRC's medical use licensees•are compatible with requirements for
those activities•regulated by the Agreement States.ÆT$”•Æ••Commissione
r Carr noted that the staff has shown good initiative•in activities in
tended to improve oversight of the medical use•of by©product material.
  He urged the staff to continue making•progress in this important are
a.•••Ô•• •‰ ? •'• •Ôcc:Á ”•”•• ÁChairman Zech•Á ”•”•• ÁCommissioner R
oberts•Á ”•”•• ÁCommissioner Carr•Á ”•”•• ÁCommissioner Rogers•Á ”•”••
 ÁCommissioner Curtiss•Á ”•”•• ÁOGC•Á ”•”•• ÁPDR © Advance•Á ”•”•• ÁDC
S © P1©124